Cancer News and Research

Latest Cancer News and Research

Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today announced that it has entered into agreements with a syndicate of institutional investors for up to $2.0 million. LifeTech Capital, a division of Aurora Capital LLC, acted as the exclusive placement agent for the financing.

17 Mar 2010

HST Global announces final negotiations to obtain needed capital to acquire first wellness center

HST Global, Inc., today announced that it is in final negotiations to obtain the needed capital to complete the acquisition of its first wellness center. This infusion of cash will allow HST to complete the wellness center acquisition and provide operating capital.

17 Mar 2010

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

Health Discovery Corporation and Smart Personalized Medicine, LLC announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information and services.

From Quest Diagnostics 17 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

SBRT improves survival in patients with inoperable non-small cell lung cancer

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group study published in the March 17 cancer-themed issue of the Journal of the American Medical Association.

17 Mar 2010

SBRT may improve survival rates for lung-cancer patients: Study

A radiation therapy that uses multiple radiation beams to target tumors precisely has been shown to eliminate the primary tumor and ultimately may improve survival rates for lung-cancer patients unable to undergo surgery, according to UT Southwestern Medical Center physicians who led a national clinical trial of the treatment.

17 Mar 2010

China Sky One Medical's 2009 fourth-quarter total revenues up 15.0%

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2009. The Company also announced its earnings guidance for full year 2010.

17 Mar 2010

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

New chemotherapy agents appear associated with improvements in survival time for patients with metastatic colorectal cancer but at substantial cost.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

17 Mar 2010

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

BeaconEquity.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

17 Mar 2010

Systemic underfunding of CDC's Division of Viral Hepatitis puts millions of Americans' health at risk

Warning that "systemic underfunding of the Centers for Disease Control's Division of Viral Hepatitis puts millions of Americans' health and well-being at risk," the National Viral Hepatitis Roundtable today called on the Administration to work with Congress to take decisive action this year to fix the funding failure for viral hepatitis screening, surveillance, and early intervention programs.

17 Mar 2010

Cord Blood America produces new edition of Corporate Profile

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ), focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced its has produced a new edition of Corporate Profile, which is used to answer inquiries about the Company from brokers, investors and other interested individuals.

17 Mar 2010

Circulating tumor cells could help guide treatment and improve quality of life for cancer patients

One of the most dangerous characteristics of cancer is its ability to metastasize, or spread through the body. For this reason, oncologists have a major need for better tests to detect cells that break away from primary tumors to travel to other parts of the body.

17 Mar 2010

Cervical cancer vaccine may protect females from post-surgical recurrence

A vaccine designed to prevent cervical cancer also may protect females from post-surgical recurrence of the disease, according to researchers at the University of Alabama at Birmingham (UAB).

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

RayStation treatment planning system receives FDA marketing clearance

RaySearch Laboratories AB has received FDA 510(k) clearance for its RayStation® treatment planning system.

17 Mar 2010

Can preventative vaccines curb the rising numbers of HIV cases?

According to a recent United Nations study, HIV infection rates among high-risk groups such as gays, drug users and sex workers are on the rise around the world.

17 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Biomoda enters into agreements with syndicate of institutional investors for up to $2.0M

HST Global announces final negotiations to obtain needed capital to acquire first wellness center

HDC, SPM enter into development and licensing agreements with Quest Diagnostics

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

SBRT improves survival in patients with inoperable non-small cell lung cancer

SBRT may improve survival rates for lung-cancer patients: Study

China Sky One Medical's 2009 fourth-quarter total revenues up 15.0%

New chemotherapy agents improve survival time for patients with metastatic colorectal cancer

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Clarient's Ovotax test may help improve patients’ response to taxane therapy

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

Systemic underfunding of CDC's Division of Viral Hepatitis puts millions of Americans' health at risk

Cord Blood America produces new edition of Corporate Profile

Circulating tumor cells could help guide treatment and improve quality of life for cancer patients

Cervical cancer vaccine may protect females from post-surgical recurrence

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

RayStation treatment planning system receives FDA marketing clearance

Can preventative vaccines curb the rising numbers of HIV cases?

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in